Expression of vascular endothelial growth factor C in human pterygium

Histochemistry and Cell Biology

Volumn 139, Issue 2, 2013, Pages 381-389

  Fukuhara, Junichi ^a   Kase, Satoru ^a   Ohashi, Tsutomu ^b   Ando, Ryo ^a   Dong, Zhenyu ^a   Noda, Kousuke ^a   Ohguchi, Takeshi ^a   Kanda, Atsuhiro ^a   Ishida, Susumu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Ohashi Eye Center   (Japan)

Author keywords

Lymphangiogenesis; Lymphatic vessel density; Pterygium; VEGF C; VEGFR 3

Indexed keywords

VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3; VEGFC PROTEIN, HUMAN; VEGFR3 PROTEIN, HUMAN;

ANTIBODY LABELING; ARTICLE; BLOOD VESSEL; CELL COUNT; CLINICAL ARTICLE; CONJUNCTIVA; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; EYE SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHATIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTERYGIUM; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; METABOLISM;

CELLS, CULTURED; HUMANS; PTERYGIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84875167945     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-012-1019-z     Document Type: Article

References (30)

1. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548-553
2. Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y, Tsuneyoshi M (2008) Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol 21:256-264
3. Bai H, Teng Y, Wong L, Jhanji V, Pang CP, Yam GH (2010) Proliferative and migratory aptitude in pterygium. Histochem Cell Biol 134:527-535
4. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE, Singh RK (2005) Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 65:9004-9011
5. Chiang CC, Cheng YW, Lin CL, Lee H, Tsai FJ, Tseng SH, Tsai YY (2007) Cyclooxygenase 2 expression in pterygium. Mol Vis 13:635-638
6. Chui J, Coroneo MT, Tat LT, Crouch R, Wakefield D, Di Girolamo N (2011) Ophthalmic pterygium: a stem cell disorder with premalignant features. Am J Pathol 178:817-827
7. Cimpean AM, Poenaru Sava M, Raica M, Ribatti D (2011) Preliminary evidence of the presence of lymphatic vessels immunoreactive for D2-40 and Prox-1 in human pterygium. Oncol Rep 26:1111-1113
8. Cursiefen C, Schlötzer-Schrehardt U, Küchle M, Sorokin L, Breiteneder-Geleff S, Alitalo K, Jackson D (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 43:2127-2135
9. Enkvetchakul O, Thanathanee O, Rangsin R, Lekhanont K, Suwan-Apichon O (2011) A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. Cornea 30:1213-1218
10. Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y (2011) RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer 47:2353-2363
11. Gebhardt M, Mentlein R, Schaudig U, Pufe T, Recker K, Nölle B, Al-Samir K, Geerling G, Paulsen FP (2005) Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 112:1023-1030
12. Herrmann E, Eltze E, Bierer S, Köpke T, Görge T, Neumann J, Hertle L, Wülfing C (2007) VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. Anticancer Res 27:3127-3133
13. Hu WG, Li JW, Feng B, Beveridge M, Yue F, Lu AG, Ma JJ, Wang ML, Guo Y, Jin XL, Zheng MH (2007) Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis. Eur Surg Res 39:229-238
14. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M, Miyazono K (2007) Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67:10181-10189
15. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:1751
16. Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Höcker M (2006) Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24:228-240
17. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92:3566-3570
18. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5:74-80
19. Kase S, Osaki M, Sato I, Takahashi S, Nakanishi K, Yoshida K, Ito H, Ohno S (2007a) Immunolocalisation of E-cadherin and beta-catenin in human pterygium. Br J Ophthalmol 91:1209-1212
20. Kase S, Takahashi S, Sato I, Nakanishi K, Yoshida K, Ohno S (2007b) Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium. Br J Ophthalmol 91:958-961
21. Liu P, Zhou J, Zhu H, Xie L, Wang F, Liu B, Shen W, Ye W, Xiang B, Zhu X, Shi R, Zhang S (2011) VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression. Cytokine 55:8-17
22. Miyata Y, Kanda S, Ohba K, Nomata K, Eguchi J, Hayashida Y, Kanetake H (2006) Tumor lymphangiogenesis in transitional cell carcinoma of the upper urinary tract: association with clinicopathological features and prognosis. J Urol 176:348-353
23. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K (2000) Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156:1499-1504
24. Padera TP, Kuo AH, Hoshida T, Liao S, Lobo J, Kozak KR, Fukumura D, Jain RK (2008) Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 7:2272-2279
25. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K (2000) VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 14:2087-2096
26. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192-198
27. Spandidos DA, Sourvinos G, Kiaris H, Tsamparlakis J (1997) Microsatellite instability and loss of heterozygosity in human pterygia. Br J Ophthalmol 81:493-496
28. Trojan L, Rensch F, Voss M, Grobholz R, Weiss C, Jackson DG, Alken P, Michel MS (2006) The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer. BJU Int 98:903-906
29. Witmer AN, van Blijswijk BC, Dai J, Hofman P, Partanen TA, Vrensen GF, Schlingemann RO (2001) VEGFR-3 in adult angiogenesis. J Pathol 195:490-497
30. Yuen D, Pytowski B, Chen L (2011) Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages. Invest Ophthalmol Vis Sci 52:2593-2597